ABOS.US Acumen Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.2180 USD
Close of Nov 13, 2026
0.1910 3.60
Market cap
USD 15.8M
P/E
-
P/B
0.48x
ROE
-303.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ABOS.US undervalued?

Graham number

The Graham number of Acumen Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Acumen Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Acumen Pharmaceuticals Inc yet.

Acumen Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirn…

Full company profile